6-methylbenzo[c]-1,6-naphthyridin-5-one | 327096-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-methylbenzo[c]-1,6-naphthyridin-5-one
• 英文别名: 6-methyl-benzo[h][1,6]naphthyridin-5(6H)-one；6-Methylbenzo[h][1,6]naphthyridin-5(6H)-one；6-methylbenzo[h][1,6]naphthyridin-5-one
• CAS: 327096-10-6
• 化学式: C₁₃H₁₀N₂O
• 分子量: 210.235
• InChiKey: ZJPXYCGVVSXWCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-Methyl-benzo[h][1,6]naphthyridin-6-ium; iodide 在 氢氧化钾 作用下， 以 水 为溶剂， 以34.5%的产率得到6-methylbenzo[c]-1,6-naphthyridin-5-one
  参考文献：
  名称：

  Alkylbenzonaphthyridinones and benzonaphthyridinium quaternary salts

  摘要：

  DOI：

  10.1007/bf02256918

文献信息

• NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Kim Myung-Hwa

  公开号：US20110218193A1

  公开（公告）日：2011-09-08

  The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.

  本发明涉及一种新型三环衍生物，具有高效的抑制聚(ADP-核糖)聚合酶（PARP）或其药用可接受盐的活性，以及其制备方法和含有该衍生物的药物组合物。本发明的三环衍生物通过抑制聚(ADP-核糖)聚合酶的活性，对于预防或治疗由过度PARP活性引起的疾病特别有效，包括神经病痛、神经退行性疾病、心血管疾病、糖尿病肾病、炎症性疾病、骨质疏松症和癌症。
• Synthesis of heterocyclic compounds using radical reactions
  作者：A.K. Ganguly、C.H. Wang、M. David、P. Bartner、T.M. Chan

  DOI：10.1016/s0040-4039(02)01537-x

  日期：2002.9

  A generalised radical reaction has been used to synthesise heterocyclic compounds which could serve as ligands for drug discovery. Attempt also have been made to rationalise the formation of oxidation products formed during TBTH reaction.

  广义自由基反应已被用于合成杂环化合物，可以用作药物发现的配体。还已经尝试使在TBTH反应期间形成的氧化产物的形成合理化。
• Efficient palladium-catalyzed direct arylation of azines and diazines using ligand-free conditions
  作者：Luca Basolo、Egle M. Beccalli、Elena Borsini、Gianluigi Broggini

  DOI：10.1016/j.tet.2009.02.025

  日期：2009.4

  The use of the palladium-catalyzed direct arylation was successfully tested on different electron-deficient heterocycles. The results demonstrate the effectiveness of the method based on the intramolecular coupling reaction providing polyazacyclic systems. This new application was obtained by using ligand-free conditions with the mixture of Pd(OAc)(2) and TBAC as catalytic system. With suitable substrates different products arising from regioselective coupling were observed. (C) 2009 Elsevier Ltd. All rights reserved.
• US8815891B2
  申请人：——

  公开号：US8815891B2

  公开（公告）日：2014-08-26
• [DE] METALLKOMPLEXE<br/>[EN] METAL COMPLEXES<br/>[FR] COMPLEXES MÉTALLIQUES
  申请人：MERCK PATENT GMBH

  公开号：WO2019158453A1

  公开（公告）日：2019-08-22

  Die vorliegende Erfindung betrifft Iridiumkomplexe, welche sich für den Einsatz in organischen Elektrolumineszenzvorrichtungen, insbesondere als Emitter, eignen. Formel (1), (2), (3), V 2 ist ausgewählt aus der Gruppe bestehend aus -CR2 -CR2 -, -CR2 -SiR2 -, -CR2 -O- oder -CR2 -NR-, wobei diese Gruppen jeweils an L 2 und an den zentralen Cyclus in Formel (2) gebunden sind.